НовостиBenzingaOppenheimer Maintains Outperform on Palvella Therapeutics, Raises Price Target to $232 Oppenheimer Maintains Outperform on Palvella Therapeutics, Raises Price Target to $232 Benzinga 2026.11.06 17:24 (GMT+0) Открыть на Benzinga Другие новости